Literature DB >> 35340456

Diagnosis of Multisystem Inflammatory Syndrome in Children in a Resource-Limited Center.

Nishanth Sekar1, Mayurathan Pakkiyaretnam1, Vaithehi Francis2.   

Abstract

Multisystem inflammatory syndrome in children (MIS-C) has become a serious disease entity following the high prevalence of coronavirus disease 2019 (COVID-19) infection with the involvement of gastrointestinal organs, kidneys, heart, and lungs. When the patient presents with mucocutaneous findings such as conjunctival injection, red lips, neurocognitive symptoms, swollen hands and lymphadenopathy, it is always highly recommended to exclude multisystem inflammatory syndrome.  As it affects multiple organs, it can result in more serious consequences. The manifestations depend largely on the organ involved. Therefore, successful management partly depends on the early diagnosis. Many treatment strategies have been put forth to tackle the disorder so far.
Copyright © 2022, Sekar et al.

Entities:  

Keywords:  children's; corticosteroids in covid-19; intravenous immunoglobulins (ivig); mis- c; sars-cov-2 related pneumonia

Year:  2022        PMID: 35340456      PMCID: PMC8930290          DOI: 10.7759/cureus.22254

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  3 in total

1.  Severe SARS-CoV-2 Infection: A Multisystem Inflammatory Syndrome in Moroccan Children.

Authors:  Amal Haoudar; Nabila Chekhlabi; Madiha Eljazouly; Chafik El Kettani; Nezha Dini
Journal:  Cureus       Date:  2021-01-29

2.  COVID-19 in children: a case report of Multisystem Inflammatory Syndrome (MIS-C) in São Paulo, Brazil.

Authors:  Elaine Monteiro Matsuda; Sinvaldo Alves Dos Santos; Marcia Jorge Castejon; Cintia Mayumi Ahagon; Ivana Barros de Campos; Luís Fernando de Macedo Brígido
Journal:  Braz J Infect Dis       Date:  2020-10-06       Impact factor: 3.257

Review 3.  Gastrointestinal, hepatic and pancreatic manifestations of COVID-19 in children.

Authors:  Francesco Pegoraro; Sandra Trapani; Giuseppe Indolfi
Journal:  Clin Res Hepatol Gastroenterol       Date:  2021-10-02       Impact factor: 3.189

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.